Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2021 | The current landscape of allogeneic CAR T-cell therapies

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, provides an overview of allogeneic chimeric antigen receptor (CAR) T-cell therapies in development. He describes ATA3219, a novel anti-CD19 CAR-T cell therapy developed for B-cell malignancies, as well as ATA2271, a mesothelin-targeted CAR-T immunotherapy for solid tumors. Tabelecleucel is an additional CAR-T cell therapy that treats Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) following hematopoietic cell or solid organ transplantation. This interview took place at Meeting on the Mesa 2021.


Pascal Touchon is the Chief Executive Officer of Atara Biotherapeutics, San Francisco, CA and a Board Member of Dantari Pharmaceuticals, Thousand Oaks, CA